Literature DB >> 27334247

Case of type 1 diabetes associated with less-dose nivolumab therapy in a melanoma patient.

Yukiko Teramoto1, Yasuhiro Nakamura1, Yuri Asami1, Taichi Imamura1, Shuji Takahira2, Manabu Nemoto2, Gota Sakai3, Akira Shimada3, Mitsuhiko Noda3, Akifumi Yamamoto1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 27334247     DOI： 10.1111/1346-8138.13486

Source DB:  PubMed          Journal:  J Dermatol        ISSN： 0385-2407            Impact factor:   4.005


× No keyword cloud information.
  17 in total

1.  Diabetes mellitus secondary to treatment with immune checkpoint inhibitors.

Authors:  V Venetsanaki; A Boutis; A Chrisoulidou; P Papakotoulas
Journal:  Curr Oncol       Date:  2019-02-01       Impact factor: 3.677

2.  Glucocorticoids did not reverse type 1 diabetes mellitus secondary to pembrolizumab in a patient with metastatic melanoma.

Authors:  Jasna Aleksova; Peter K H Lau; Georgia Soldatos; Grant McArthur
Journal:  BMJ Case Rep       Date:  2016-11-23

Review 3.  Melanoma and Immune Checkpoint Inhibitors.

Authors:  Masutaka Furue; Takamichi Ito; Naoko Wada; Maiko Wada; Takafumi Kadono; Hiroshi Uchi
Journal:  Curr Oncol Rep       Date:  2018-03-23       Impact factor: 5.075

4.  New onset diabetes after nivolumab treatment.

Authors:  Ricardo Capitao; Carlos Bello; Ricardo Fonseca; Catarina Saraiva
Journal:  BMJ Case Rep       Date:  2018-01-29

Review 5.  Is immune checkpoint inhibitor-associated diabetes the same as fulminant type 1 diabetes mellitus?

Authors:  Angelos Kyriacou; Eka Melson; Wentin Chen; Punith Kempegowda
Journal:  Clin Med (Lond)       Date:  2020-07       Impact factor: 2.659

Review 6.  Endocrine Toxicity of Cancer Immunotherapy Targeting Immune Checkpoints.

Authors:  Lee-Shing Chang; Romualdo Barroso-Sousa; Sara M Tolaney; F Stephen Hodi; Ursula B Kaiser; Le Min
Journal:  Endocr Rev       Date:  2019-02-01       Impact factor: 19.871

Review 7.  Spectrum of immune checkpoint inhibitors-induced endocrinopathies in cancer patients: a scoping review of case reports.

Authors:  Meng H Tan; Ravi Iyengar; Kara Mizokami-Stout; Sarah Yentz; Mark P MacEachern; Li Yan Shen; Bruce Redman; Roma Gianchandani
Journal:  Clin Diabetes Endocrinol       Date:  2019-01-22

Review 8.  Diabetes mellitus induced by immune checkpoint inhibitors: type 1 diabetes variant or new clinical entity? Review of the literature.

Authors:  V Lo Preiato; S Salvagni; C Ricci; A Ardizzoni; U Pagotto; C Pelusi
Journal:  Rev Endocr Metab Disord       Date:  2021-01-06       Impact factor: 6.514

9.  Immune Checkpoint Inhibitor-Associated Type 1 Diabetes Mellitus: Case Series, Review of the Literature, and Optimal Management.

Authors:  Jonathan Kapke; Zachary Shaheen; Deepak Kilari; Paul Knudson; Stuart Wong
Journal:  Case Rep Oncol       Date:  2017-10-17

10.  Characteristics and clinical course of type 1 diabetes mellitus related to anti-programmed cell death-1 therapy.

Authors:  Megu Yamaguchi Baden; Akihisa Imagawa; Norio Abiru; Takuya Awata; Hiroshi Ikegami; Yasuko Uchigata; Yoichi Oikawa; Haruhiko Osawa; Hiroshi Kajio; Eiji Kawasaki; Yumiko Kawabata; Junji Kozawa; Akira Shimada; Kazuma Takahashi; Shoichiro Tanaka; Daisuke Chujo; Tomoyasu Fukui; Junnosuke Miura; Kazuki Yasuda; Hisafumi Yasuda; Tetsuro Kobayashi; Toshiaki Hanafusa
Journal:  Diabetol Int       Date:  2018-07-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.